Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases

Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin

Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617

Machine learning driven bioequivalence risk assessment at an early stage of generic drug development

Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

Ginkgo biloba extract safety: Insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events

Knowledge, Attitude, and Practice Regarding Pharmacovigilance and Barriers to Reporting Adverse Drug Reactions Among the General Population in Saudi Arabia

Lichenoid Drug Eruption Secondary to Systemic Antibiotics: Case Report

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir

Pharmacovigilance monitoring and treatment adherence in patients on antihypertensive drugs at a tertiary care centre

Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis

Uma breve revisão sobre Farmacovigilância: histórico, conceitos, aplicações e resoluções norteadoras

Adverse Drug Reactions to β-Lactam Antibiotics: A Portuguese Pharmacovigilance Database Analysis

Exploring drug-induced toxic epidermal necrolysis: A case series and comprehensive review

Posición de la Academia Nacional de Medicina respecto a la disposición de la ANMAT que cataloga a los inhibidores de la bomba de protones (IBP) como de “venta libre”

Developing a Screening Strategy to Identify Hepatotoxicity and Drug Interaction Potential of Botanicals

Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study

Exploring Human Misuse and Abuse of Veterinary Drugs: A Descriptive Pharmacovigilance Analysis Utilising the Food and Drug Administration’s Adverse Events Reporting System (FAERS)

The Food and Drug Administration's Safety Surveillance of Adverse Event Cases Involving Cannabinoid Hemp Products, 2019–2023

Influence of inpatient withdrawal treatment on drug safety in alcohol use disorder — a quasi-experimental pre-post study

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a real-world analysis from FAERS database

Can Pharmacovigilance Data Represent a Potential Tool for Early Detection of the Antibiotic Resistance Phenomenon?

Practices and awareness of pharmacovigilance in ALERT hospital, Addis Ababa, Ethiopia, a pilot study

General selection criteria for safety and patient benefit [XⅢ]: Comparing the formulation characteristics of brand-name and generic bifonazole creams

Comparative safety of different antibiotic regimens for the treatment of outpatient community-acquired pneumonia among otherwise healthy adults

Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine

ASSESMENT OF ATTITUDE AND PRACTICE TOWARDS ADVERSE DRUG REACTION REPORTING OF HEALTH PROFESSIONALS IN REPUBLIC OF NORTH MACEDONIA

Educate to Reduce Unnecessary Antibiotic Prescriptions

Using digital health technologies to optimise antimicrobial use globally

How Will Trump’s Government Impact Health Policy Abroad?

El PRAN celebra 10 años de retos y logros en su jornada anual por el Día Europeo para el Uso Prudente de los Antibióticos

Machine learning algorithms for prediction of measles one vaccination dropout among 12–23 months children in Ethiopia

Reassuring Data on GLP-1 RAs and Pancreatic Cancer Risk

FDA Updates GLP-1 Label With Pulmonary Aspiration Warning

First Trimester Tetracycline Exposure and Risk of Major Congenital Malformations

Collaborative Real-World Evidence Among Regulators: Lessons and Perspectives

Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)

DNA-Based Chemical Unclonable Functions for Cryptographic Anticounterfeit Tagging of Pharmaceuticals